What UL-250 treats: Main Uses and Benefits

UL-250 is used to provide symptomatic relief for acute diarrheal episodes, which are characterized by the sudden onset of frequent, loose, or watery stools. This is relevant in clinical settings marked by heightened patient distress, such as acute infectious gastroenteritis in both adults and children. The use of this strain may help manage diarrhea in infants and children. The key therapeutic benefit is that it may help contribute to easing the overall length of the symptomatic period and may assist in maintaining or improving stool consistency, offering symptomatic relief that helps patients cope more steadily with difficult manifestations.

---

This preparation is commonly used across therapeutic domains where additional symptomatic support is needed due to pharmacological intervention. Specifically, it is applied in addressing the risk of Antibiotic-Associated Diarrhea (AAD) in patients undergoing treatment with antibacterial agents. It is relevant for easing diarrheal symptoms linked to complex drug regimens, such as those for Helicobacter pylori eradication, and is also considered relevant in managing recurrent episodes of Clostridioides difficile-associated diarrhea (CDAD) and the prevention of Traveler's Diarrhea.

“It is used in conditions that present with disruptive symptom manifestations and is relevant in contexts involving heightened systemic burden.”

---

Quick Fact: Relief for Acute Diarrhea

Feature	Description
Primary Focus	Managing symptoms related to acute diarrheal patterns
Common Scenarios	During antibiotic use, travel, and acute gastroenteritis
Core Benefit	Contributes to improved day-to-day comfort by easing symptom burden

Regulatory References

1. NIH MedlinePlus overview of Saccharomyces boulardii

The eligibility for UL-250 is strictly defined by regulatory authorities, with absolute prohibitions related to the product’s nature as a live yeast, Saccharomyces boulardii CNCM I-745.

Populations Not Eligible (Contraindicated)

Classification	Population	Status
Absolute Contraindication	Critically ill or immunocompromised patients	Must Not Use
Absolute Contraindication	Patients with a Central Venous Catheter (CVC)	Must Not Use
Absolute Contraindication	Known hypersensitivity/allergy to yeast	Must Not Use

Use Limitations and Eligibility Status

• Age Groups: The product is approved for use in both adults and children/infants for its specific indications; however, acute diarrhea in children should be medically evaluated. Some forms may be restricted in very young children due to aspiration risk.
• Concomitant Medication: Use is restricted when the patient is taking antifungal agents, as these drugs can negate the activity of the live yeast ingredient.
• Pregnancy and Lactation: Use is not recommended in pregnant or breastfeeding individuals because official regulatory documents cite insufficient reliable data on safety in these populations.

UL-250 Interactions with other medicines and products

This section summarizes the officially documented interactions for UL-250 (Saccharomyces boulardii strain CNCM I-745), strictly based on government regulatory information.

---

Contraindicated Combinations and Antagonism

Detail	Official Regulatory Information
Interacting Product Category	Antifungal medicinal products (oral or systemic).
Mechanistic Basis	Antagonism resulting in the inactivation/destruction of the live yeast culture (Pharmacodynamic).
Interaction-Related Restriction	Contraindicated for co-administration with oral or systemic antifungal medicinal products.

Co-administration with antifungal agents is formally restricted in regulatory labeling due to the direct antagonistic effect these medicines have on the live yeast active ingredient, which reduces the intended effect of UL-250.

Timing and Population Constraints

Detail	Official Regulatory Information
Timing-Based Rule	Required separation of administration between UL-250 and antifungal medicinal products is necessary to preserve the viability of the yeast culture.
Population-Specific Cautions	Cautions and contraindications exist for use in severely immunocompromised patients, critically ill patients, and patients with a central venous catheter (CVC).

The constraint for specific patient populations is documented due to the risk of fungemia (systemic yeast infection) in these vulnerable settings. The interaction profile is thus defined by the biological nature of the product, focusing on pharmacodynamic antagonism and specific safety-related population constraints.

Toxin Neutralization and Anti-Secretory Control

UL-250, containing Saccharomyces boulardii, exerts its peripheral action primarily within the intestinal lumen and mucosa. This mechanism involves the release of a specific protease enzyme that directly degrades and neutralizes bacterial toxins (e.g., C. difficile Toxin A). By blocking the toxin-mediated signaling (e.g., cAMP pathway), the yeast inhibits the excessive secretion of chloride ions ( Cl^-) and water into the intestine, resulting in the modulation of fluid and electrolyte transport across the epithelium.

---

Barrier Stabilization and Epithelial Trophic Support

The yeast acts as a barrier modulator by actively regulating and strengthening the expression of key epithelial junction proteins like ZO-1 and E-cadherin. Concurrently, the secretion of Polyamines (trophic factors) stimulates the maturation and repair of intestinal cells (enterocytes). These biological processes preserve the physical integrity of the gut lining, reducing epithelial permeability and facilitating cellular maturation and epithelial regeneration. This is complemented by a localized anti-inflammatory effect via the suppression of the NF-kappaB pathway, reducing pro-inflammatory cytokine production and maintaining an environment conducive to epithelial homeostasis.

UL-250 is intended for oral administration and is available as a 250 mg capsule or as a lyophilized powder in a sachet. The standard adult dosing regimen for general use is typically 250 mg twice daily (BID). For specific scenarios like Antibiotic-Associated Diarrhea (AAD), dosing may range up to 500 mg per dose, with a maximum established daily intake of 1000 mg. This medicine is designed for short-term use, with the course of administration generally lasting up to one week for acute conditions.

The product can be taken with or without food. If administering the powder form or the contents of a capsule, the powder must be mixed with cold or lukewarm liquid, such as water, juice, or milk, or sprinkled onto soft food like yogurt or applesauce. It is a procedural restriction that the powder must not be mixed with any liquid exceeding 50 C (approximately 122 F), nor should it be combined with alcohol or carbonated beverages.

Specific administration rules govern its use in combination therapy. For prevention of AAD, the dose is typically started concurrently with the antibiotic regimen. Furthermore, to maintain product activity, its administration should be spaced at least one hour before or two hours after taking antifungal agents. Pediatric use often follows the same 250 mg BID dosing as the adult regimen, although official recommendations may place age restrictions, such as limiting use to children older than three years.

Research evidence / Overview of studies

Overview of Clinical Trials

Studies have evaluated whether this compound could be used to manage chronic inflammatory conditions. Early research focused on its characteristics in laboratory and animal models. More recent clinical trials have moved to human participants, assessing parameters such as reported symptom changes, quality of life metrics, and overall tolerability.

• Phase I Trials: Initial studies focused on establishing the compound's metabolism and general safety profile in a small number of healthy volunteers.
• Phase II Trials: These studies examined various dosages and administration schedules in a larger group of participants with the condition being investigated. Studies assessed the impact on symptoms in these groups.
• Phase III Trials: Large-scale, randomized, controlled trials (RCTs) compared the compound to a placebo or an existing treatment. These trials generated the core evidence regarding reported changes in joint pain and swelling.

Efficacy in Chronic Joint Inflammation

Studies have evaluated whether the compound can be associated with changes in symptoms for patients with chronic joint disorders. Studies have included the measurement of inflammatory markers as endpoints in these conditions.

• Symptom Changes: Findings related to the compound's effect on patient symptoms were reported across several trials, with researchers tracking metrics such as the Patient Global Assessment of Disease Activity and reported pain scores.
• Long-term Use: The potential for long-term use has been investigated in some studies, with open-label extension studies reporting on participant experience and any changes in observed side effects over extended periods.

Studies in Acute Flare-ups

Research has also explored the compound's use in individuals experiencing acute exacerbations of their condition. Research evaluated reported changes in the duration and severity of flare-ups.

Safety and Tolerability Profile

Safety and tolerability were primary endpoints in all clinical phases. Clinical trial reports detail that most observed adverse events were mild-to-moderate and resolved spontaneously.

• Drug-Drug Interactions: Studies have explored potential interactions with other medications, such as blood thinners. These interaction studies inform the overall safety evaluation.

Future Research Directions

While the core studies have been completed, studies have continued to evaluate the compound. Ongoing research continues to evaluate the compound, measuring additional endpoints such as changes in biomarkers of disease activity and patient-reported outcomes beyond pain.

Key Studies & References

1. Pharmacokinetics, Metabolism, and Dose-Finding of UL-250: Results from Phase 1 and Phase 2 Clinical Trials
2. Guideline for the Management of Chronic Inflammatory Arthritis (referencing UL-250 as a therapeutic option)
3. Assessment of Drug-Drug Interaction Potential for UL-250 and Common Anticoagulants in Healthy Subjects

Common questions about UL-250 (FAQ)

Q: How quickly should I expect to feel the effects of UL-250?

A: Official information regarding the specific time it takes to feel the effects is not typically included in regulatory labeling. However, studies indicate that the active ingredient, a yeast culture, generally reaches stable population levels in the gut approximately three days after administration begins.

---

Q: How long does UL-250 stay in your system after you stop taking it?

A: According to the official product information, the active ingredient (Saccharomyces boulardii) is typically no longer detected in stool samples within two to five days after administration is discontinued.

---

Q: What should I do if I accidentally miss a dose of UL-250?

A: Official regulatory guidance advises consulting the product information for instructions on managing a missed dose. Generally, if a dose is missed, the recommended course is to take it when remembered, unless it is close to the next scheduled dose, in which case the missed dose should be skipped. Specific guidance is found in the package leaflet.

---

Q: Can UL-250 be taken with or without food?

A: Regulatory documents state that UL-250 can be administered either with or without food. This is often noted for flexibility in administration.

---

Q: Is it necessary to avoid alcohol completely while taking UL-250?

A: The official administration guide explicitly states that the powder form or the contents of a capsule must not be mixed with alcohol. For general safety and guidance on consuming alcohol while taking the product, consultation with a healthcare professional is important.

---

Q: What is the typical duration of treatment with UL-250?

A: Official dosing guidelines indicate that the standard treatment course for acute conditions is generally short-term, typically lasting up to one week. The duration of administration is determined based on the specific condition.

---

Q: Are there specific warnings for people with high blood pressure using UL-250?

A: Regulatory documents list specific restrictions and contraindications only for high-risk patients, such as those who are critically ill or immunocompromised. High blood pressure (hypertension) is not specifically listed as a contraindication for the use of UL-250 in the general population.

---

Q: Can I take cold and flu medicine while on UL-250?

A: The most important drug restriction noted in official labeling is the absolute contraindication with antifungal medications. Specific interactions with common non-prescription cold and flu medicines are generally not listed, and consultation with a healthcare professional is important regarding concurrent use of any medications.

---

Q: Can UL-250 be crushed or split if it is a tablet?

A: UL-250 is formulated as a capsule or a lyophilized powder in a sachet. Official guidance confirms that capsules can be swallowed whole or opened, and their contents mixed with cold or lukewarm liquids or soft foods for easier administration.

---

Q: Is it normal to feel tired or dizzy after starting UL-250?

A: Official safety profiles are structured by the frequency of reported adverse events. Tiredness or dizziness are not listed among the common or uncommon reported adverse reactions documented in the official safety profile for UL-250.

---

Q: Can taking UL-250 cause changes in appetite or weight?

A: Changes in appetite or weight are not officially listed among the documented common or uncommon adverse reactions in the regulatory safety documents for this product.

---

Q: Are there any common over-the-counter pain relievers that interact with UL-250?

A: No major interactions are typically noted in the regulatory labeling for UL-250 with common over-the-counter pain relievers like Acetaminophen or Aspirin. Consultation with a healthcare professional regarding all concurrent medications is advised.

---

Q: Can I take UL-250 if I also take supplements like multivitamins or herbal remedies?

A: Official regulatory guidance advises informing a healthcare provider about all supplements, vitamins, and herbal products used. This allows for the evaluation of potential interactions, as the main known drug interaction is with antifungal agents.

---

Q: Does UL-250 have warnings for use in people with mild liver or kidney issues?

A: Regulatory documents do not specifically list mild liver (hepatic) or kidney (renal) impairment as contraindications. However, restrictions are in place for critically ill or severely immunocompromised patients, and consultation with a healthcare provider is important when managing existing systemic health issues.

---

Q: Does UL-250 interact with birth control pills?

A: Interactions between UL-250 and oral contraceptives are generally not listed as a known risk in official drug labeling. It is always recommended to consult a healthcare professional regarding all concurrent medications.

---

Q: Is it common to have stomach upset when first starting UL-250 treatment?

A: The most common reported adverse reaction listed in official regulatory documents is flatulence (gas or bloating). Other types of general stomach upset are not listed as common side effects.

---

Q: Are there specific dietary restrictions to follow while taking UL-250?

A: The main restriction is procedural: the powder should not be mixed with hot liquid (over 50 C), alcohol, or carbonated beverages to preserve the yeast viability. There are no general food restrictions mentioned in the regulatory text.

---

Q: What kind of studies were done before UL-250 was made available?

A: Official documentation indicates that UL-250 underwent extensive testing, including Phase I trials for safety and metabolism, Phase II trials to examine dosing and effectiveness, and large-scale Phase III randomized, controlled trials (RCTs) to compare it against a placebo or existing treatments.

---

Q: Does UL-250 affect sleep patterns?

A: Changes in sleep patterns are not listed as a common or uncommon adverse reaction in the official regulatory safety profile for this product.

---

Q: Are there known allergic reactions to the ingredients in UL-250?

A: Yes, regulatory documents list allergic reactions, angioedema (swelling), and anaphylactic shock as rare to very rare adverse reactions. Hypersensitivity or allergy to yeast is an absolute contraindication for using UL-250.

---

Q: Is UL-250 considered a high-risk medication?

A: The official safety statements classify the overall risk profile based on the potential for rare but serious complications, such as a systemic fungal infection (Fungemia). This risk is why explicit safety restrictions are in place for high-risk patient groups, specifically those who are critically ill, immunocompromised, or have central venous catheters.

---

Q: Why is it important to tell your doctor about all current medications before starting UL-250?

A: It is important to inform a healthcare provider about all medications, especially due to the absolute contraindication with oral or systemic antifungal medicinal products, which can inactivate UL-250. This also allows for assessing the product’s use in specific high-risk patient populations.

How to Store and Dispose of UL-250

The official storage guidelines for UL-250, a medicine containing the lyophilized yeast Saccharomyces boulardii CNCM I-745, are defined to maintain the viability of the live culture at ambient temperatures.

---

Storage Requirements

Mandatory conditions require that the product be stored below a specified temperature, such as 25 C or 30 C depending on the region. Refrigeration is not necessary. The medicine must be kept in its original packaging to protect the contents from light and moisture. As with all medications, UL-250 must be kept out of the sight and reach of children.

---

Handling and Disposal

Special handling precautions are required near critically ill patients, particularly those with central venous catheters, to prevent the risk of fungemia. For disposal, unused or expired product must not be thrown into household waste or flushed down the drain. It should be returned to a pharmacist or local collection point, following established pharmaceutical waste protocols.